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Abstract 
Background & Aims: In order to understand the role of miRNAs in renal tumorigenesis, 
we undertook a stepwise approach that included a comprehensive differential miRNA ex-
pression analysis for the most common histological subtypes of human renal neoplasms ap-
pearing in either sporadic or hereditary forms. We also aimed to test the hypothesis that 
microRNAs can act as an alternative mechanism of VHL gene inactivation and therefore might 
be correlated with tumorigenesis in ccRCC. Finally, we wanted to explore whether the 
well-known hypoxic activation of ccRCC is followed by a specific pattern of miRNA ex-
pression.  
Methods: Tumor and normal adjacent kidney parenchyma from patients with RCC were 
tested for microRNA expression. Twenty cases of different histologies were used for profiling 
by PCR miRNA arrays. For validation, a separate cohort of samples used to test specifically 
miR92a expression and its involvement in VHL gene mRNA silencing. Finally, miR210 as a 
marker of hypoxia was evaluated. Expression values were correlated with important clini-
copathologic features from the patients. 
Results: We identified unique miRNA expression signatures for each histologic subtype of 
kidney  tumors.  Expression  values  for  downregulated  miRNAs  ranged  from  0.3-fold  (in 
VHL-clear cell RCC) up to 0.393 fold (in papillary type II (HLRCC) tumors). For the upreg-
ulated miRNAs, fold-changes ranged from 2.1 up to 290-fold. Specific patterns together with 
type-specific profiles were observed. Twenty-three miRNAs were found to be differentially 
expressed in both sporadic and VHL-dependent ccRCC. Sporadic clear cell tumors showed a 
unique pattern of 14-miRNA that were absent from the VHL-dependent tumors. These also 
showed 15 miRNAs specific to the hereditary type. Common miRNAs to both sporadic and 
hereditary forms included miR-92a and miR-210. For miR-92a, and a striking inverse corre-
lation with VHL mRNA levels was found. For the hypoxia-regulated miR-210, clear cell tumors 
showed significantly higher expression levels when compared to tumor of non-clear cell 
histology (9.90-fold vs. 1.36, p<0.001). 
Conclusions: microRNA expression seems to be involved in every step of RCC patho-
genesis: both as an element for tumor development as well as a consequence of or in response 
to the initial malignant transformation and part of tumor progression. Our data show con-
sistent disregulation of miRNAs in human kidney cancer, some of which are potentially in-
volved in critical gene silencing in RCC and others that are activated as part of the patho-
physiological response in these tumors. 
Key words: miRNA, VHL, RCC, ccRCC, BHD, HLRCC, TSC, BHD. 
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Introduction 
Renal cell carcinoma (RCC) is the most common 
epithelial malignancy of the kidney in adults, repre-
senting  over  90  percent  of  the  primary  renal  neo-
plasms and accounts for approximately 3% of all adult 
malignancies  in  western  countries.  In  the  United 
States, 58,000 new cases were diagnosed in 2010 with 
approximately 13,000 deaths (1). The worldwide in-
cidence and mortality rate is in the order of 270,000 
cases and 120,000 deaths respectively (2). 
RCC is also a complex and partially understood 
disease. However, significant advances in the classi-
fication  of  the  disease  during  the  last  decade  have 
resulted from the combined application of molecular 
biology techniques and thorough histological exami-
nation  of  tumors.  These  advances  have  shown  that 
renal epithelial neoplasms are not a single tumor but 
rather a group of distinguishable entities (3).  
In several types of human cancer, gene and pro-
tein expression studies have demonstrated to be use-
ful for classifying tumors and identifying unique mo-
lecular  biomarkers  (4-7).  More  recently,  microRNA 
(miRNA) expression studies have appeared trying to 
establish  molecular  classification  of  tumors  (8-11). 
microRNAs are a class of small RNAs that are phylo-
genetically conserved and play important roles in the 
regulation of cell survival, proliferation and differen-
tiation through post-transcriptional regulation of gene 
expression (12). Although the functions of most of the 
identified miRNAs have yet to be determined, their 
use  as  potential  biomarkers  has  been  considered  in 
several human diseases and cancers (13, 14). 
microRNA-mediated regulation of tumorigenesis 
has emerged as a new paradigm in the field of cancer 
biology. Accumulated studies show that miRNAs are 
frequently deregulated in hematologic and solid hu-
man malignancies and may function as either onco-
genes or tumor suppressor genes (15). This class of 
microRNAs has been termed oncomiRs, and alteration 
in  their  expression  has  been  causatively  linked  to 
cancer development and disease outcome. Thus, the 
clinical value of these miRNAs as novel biomarkers 
for different aspect of RCC management is being ac-
tively investigated. 
Clear  cell  RCC  (ccRCC)  is  the  most  common 
histologic subtype of kidney cancer, and accounts for 
approximately 70% of the cases (16), and loss of func-
tion of the von Hippel Lindau (VHL) tumor suppres-
sor  gene  is  a  well-known  mechanism  in  the  patho-
genesis of hereditary and sporadic ccRCCs (17). Al-
lelic inactivation of the VHL gene has been shown to 
occur  through  mutation,  DNA  methylation,  and/or 
chromosomal  loss  in  the  majority  of  ccRCCs  (18), 
which  leads  to  enhanced  transcriptional  activity  of 
Hypoxia  Inducible  Factor  1  alpha  (HIF-1α)  and  the 
resulting hypoxic pattern of gene expression (19).  
Tumor hypoxia  has been  shown to be a prog-
nostic factor in solid tumors (20-22). Many non-renal 
cancers  are  characterized  by  hypoxia,  enhanced 
HIF-1α  levels  and  increased  expression  of  hypox-
ia-regulated genes, which correlate both with tumor 
progression and patient outcome (23, 24). microRNAs 
have  also  been  shown  to  be  altered  in  response  to 
hypoxia  (25).  Particularly,  the  hypoxia-responsive 
miR-210 has been described to be upregulated in hy-
poxic tumors (26-28). 
In order to understand the role of miRNA in re-
nal tumorigenesis, we undertook a stepwise approach 
that  included  a  comprehensive  differential  miRNA 
expression analysis for the most common histological 
subtypes of human renal neoplasms including clear 
cell RCC (ccRCC), papillary RCC, chromophobe RCC 
and  the  closely  related  benign  tumor  oncocytomas, 
some of them appearing in either sporadic or heredi-
tary forms. We also aimed to test the hypothesis that 
microRNAs  can  act  as  an  alternative  mechanism  of 
VHL gene inactivation and therefore might be corre-
lated  with  tumorigenesis  in  ccRCC.  Finally,  we 
wanted to explore whether the well-known hypoxic 
activation of ccRCC is followed by a specific pattern of 
miRNA expression.  
Materials and Methods 
Tissues  and  sample  preparation:  Fresh  frozen 
tumor and normal kidney samples from 20 RCC pa-
tients  were  used  for  miRNA  expression  profiling. 
Morphology  included  clear  cell  (both  sporadic  and 
VHL),  papillary  type  I,  chromophobe,  hybrid  onco-
cytic  (Birt-Hogg-Dube  (BHD)),  oncocytomas,  papil-
lary  type  II  (HLRCC),  Tuberous  Sclerosis  Complex 
(TSC), and Succinate Dehydrogenase B (SDHB) kid-
ney tumors. For validation, a separate cohort of for-
ty-three  FFPE  tumor  samples  and  corresponding 
normal kidney from 39 patients was used to assess 
miRNAs targeting the VHL gene and hypoxia-driven 
miR-210 expression. These samples included 21 spo-
radic clear cell RCCs, fifteen CCRCC arising in VHL 
syndrome, and 2 clear cell tumors in BHD patients. 
Three hybrid oncocytic tumors, one papillary type I 
and one tumor with sarcomatoid differentiation were 
also included for analysis. Five micron-thick samples 
mounted on glass slides were needle microdissected 
and  two  protocols  for  either  total  RNA  or  miRNA 
extraction were used in the samples.   Journal of Cancer 2011, 2 
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Cell  lines:  Two  normal  epithelial  cell  lines 
(HRCE  (Lonza,  Basel,  Switzerland),  HK-2  (ATCC, 
Manassas,  VA),  one  embryonic  kidney  cell  line 
(HEK293T (ATCC)) and 2 clear cell kidney cancer cell 
lines (786.O (ATCC), UOK117) were used. Cells were 
grown  in  DMEM  supplemented  with  10% 
heat-inactivated FBS in a 5% CO2 atmosphere. At 80% 
confluence, cells were harvested after trypsinization 
for  simultaneous  total  and  microRNA  extraction 
(miRNAeasy®, Invitrogen, Carlsbad CA). Quality and 
concentration of total RNA and microRNA were as-
sessed  by  260/280  spectrophotometry  ratio 
(Nanodrop®, Thermo Scientific, Wilmington, DE) and 
by  the  Agilent  bioanalyzer®  (Agilent,  Santa  Clara, 
CA). 
miRNA arrays and miRNA analysis: Extracted 
total  or  miRNA  (10  ng/µl)  was  reverse  transcribed 
using universal poly-A tailing of all microRNAs fol-
lowing manufacturer’s recommendations (SA Biosci-
ences, Frederick MD). PCR-based arrays containing a 
panel  of  88  miRNAs  and  4  small  nucleolar  RNAs 
(snoRNA)  used  for  normalization.  miRNA-specific 
stem-loop primers (Applied Biosystems,  Foster City 
CA) were used for microRNAs targeting VHL and for 
miR-210  analysis.  One  µl  was  used  in  a  12  µl  final 
volume  reaction  for  Real-time  PCR  analysis  on  an 
Applied  Biosystems  Step-One  Plus®  real  time  PCR 
system. Two small nucleolar RNAs, RNU6B and Z30 
were used as internal controls. Relative amounts were 
calculated by the ΔCT method and further normalized 
to the values of either the normal cell lines or the cor-
responding normal kidney for the tissue samples. 
Differential  miRNA  expression  profiling:  Dif-
ferentially expressed miRNAs for each of the histo-
logic subtypes as compared to normal kidney were 
defined as those with a two-fold change and a false 
discovery  rate  <5%.  Supervised  and  unsupervised 
clustering was used to evaluate the role of these his-
tology-specific miRNAs for the diagnosis of RCC. 
Database  search  and  VHL-targeting  miRNA 
identification:  Three  miRNA  prediction  databases 
(MIRANDA [http://www.microrna.org/microrna/], 
SANGER  [http://microrna.sanger.ac.uk/]  and 
TARGETSCAN [http://www.targetscan.org/]) were 
interrogated for microRNAs having the VHL gene as a 
target.  Integrated  outputs  for  common  overlapping 
miRNAs  were  identified  by  a  intersecting  the  list 
through Venn diagrams. 
VHL gene mRNA expression: Two gene-specific 
primers and FAM-MGB fluorescent probes sets were 
used for VHL mRNA quantification (Taqman® gene 
expression  assays)  by  Real-time  PCR.  Relative  ex-
pression to normal cell lines or normal adjacent kid-
ney  was  used,  normalized  to  cyclophilin  A  (PPIA) 
expression as internal control. 
Statistical analysis: A two-fold change (up or 
down) in either microRNA or gene expression relative 
to normal kidney was considered as significant. Mi-
croRNA expression was also correlated to the clini-
copathologic features of the tumors. The relationship 
between  expression  values  and  these  variables  was 
evaluated  by  the  Mann-Whitney  or  Kruskall-Wallis 
non-parametric  tests.  For  categorical  variables,  Chi 
square tests were used with Fisher’s correction where 
appropriate.  Statistical  significance  was  defined  as 
p<0.05. 
 
Results 
Renal cell carcinomas show unique miRNA 
expression profiles 
We identified unique miRNA expression signa-
tures  for  each  histologic  subtype  of  kidney  tumors. 
The  clinicopathologic  characteristics  of  the  patients 
and samples used for miRNA profiling are shown in 
Table 1. Expression values for downregulated miR-
NAs ranged from 0.3-fold (in VHL-clear cell RCC) up 
to 0.393 fold (in papillary type II (HLRCC) tumors). 
Commonly  lost  miRNAs  in  clear  cell  tumors  (both 
sporadic  and  clear  cell)  included  miR-184  and 
miR-206,  while  miR-122  and  -143  were  the  most 
commonly downregulated in Papillary type I tumors. 
For  the  upregulated  miRNAs,  fold-changes  ranged 
from  2.058  up  to  290-fold.  Most  differentially  ex-
pressed genes were from HLRCC Pap-II cases. Over-
expressed  miRNAs  included  miR-92a  in  clear  cell 
RCC (2.28-fold, p<0.001), miR-183 in papillary type I 
(29-fold), miR-10a and -10b in papillary type II tumors 
(240-fold  and  290-fold),  miR-203  in  chromophobe 
tumors, and miRNas 210/let7i in TSC2 renal tumors.  
Unsupervised hierarchical clustering of tumors 
based on miRNA expression values showed two ma-
jor  clusters  of  samples  (Figure  1).  The  first  cluster 
grouped both the normal kidney and tumors derived 
from the proximal nephron (i.e. clear cell and papil-
lary type I). Sporadic ccRCC as well as those tumors 
arising  within  VHL  syndrome  showed  very  similar 
expression  pattern.  The  second  major  cluster  con-
tained tumors that are thought arise from the distal 
nephron,  including  benign  oncocytomas  and  chro-
mophobe RCCs. 
Specific  patterns  together  with  type-specific 
profiles were observed. Twenty-three miRNAs were 
found to be differentially expressed in both sporadic 
and  VHL-dependent  ccRCC.  Sporadic  clear  cell  tu-
mors  showed  a  unique  pattern  of  14-miRNA  that  Journal of Cancer 2011, 2 
 
http://www.jcancer.org 
518 
were absent from the VHL-dependent tumors. These 
also  showed  15  miRNAs  specific  to  the  hereditary 
type. Common miRNAs to both sporadic and heredi-
tary forms included miR-92a and miR-210 (Table 2). 
  Journal of Cancer 2011, 2 
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Figure 1. Unsupervised hierarchical clustering of RCC samples based on microRNA expression values. Two major clusters 
of samples were generated: a “proximal tubule origin” group that included clear cell RCCs either sporadic or hereditary, and 
papillary type I RCC. The second group included “distal tubule origin” samples that consisted of benign oncocytomas, hybrid 
oncocytic tumors from BHD patients and sporadic chromophobe tumors. This clustering indeed follows our current un-
derstanding of the biologic and anatomical origin of these tumors. 
  Journal of Cancer 2011, 2 
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Table 1. Clinicopathologic characteristics of the patients and samples used for miRNA profiling.  
 
Abbreviations: VHL: Von-Hippel Lindau; BDH: Birt-Hogg-Dube; BMF: Bilateral Multifocal; HLRCC: Hereditary Leiomyomatosis Renal Cell 
Carcinoma; SDHB: Succinate Dehydrogenase B; TSC: Tuberous Sclerosis Complex. 
 
Table 2. Common and unique miRNAs to both sporadic and hereditary forms of clear cell RCCs. 
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Another  major  finding  was  the  differential  ex-
pression  of  two  closely  related  histologic  subtypes: 
renal  oncocytomas  and  chromophobe  tumors.  The 
comparison  demonstrated  that  these  entities  share 
most  of  the  miRNAs  expressed.  Chromophobe  tu-
mors  (77  miRNAs),  hybrid  oncocytic  lesions  (77 
miRNAs) and renal oncocytomas (68 miRNas) had 57 
miRNAs in common, and only a subset of 6, 2, and 1 
miRNAs  respectively  were  unique  to  each  group 
(Figure 2).  
 
 
Figure 2. Venn diagram showing the common and unique 
microRNAs expressed in the closely related chromophobe 
tumors,  hybrid  oncocytic  and  benign  oncocytomas.  Up-
regulated  microRNAs  are  highlighted  in  red,  whereas 
downregulated ones are in blue. 
 
miR-92a has negative regulatory effects over 
VHL gene  
To test the hypothesis that miRNAs may have 
regulatory  effects  on  the  VHL  gene  and  therefore 
might  be  implicated  in  ccRCC  tumorigenesis,  three 
major miRNA databases with alternative algorithms 
to  determine  potential  miRNA-mRNA  interactions 
and containing expected targets were interrogated to 
find miRNAs targeting the VHL gene. Four sequences 
were  identified:  miR-92a,  miR-143,  miR-320  and 
miR-519d  with  several  sites  of  miRNA  interactions 
throughout the VHL gene sequence. It is noteworthy 
that miR-92a came out as a common denominator of 
clear cell tumors in the profiling of all RCCs (Table 2). 
Forty-three ccRCCs were evaluated for the expression 
of these 4 miRNAs together with VHL gene mRNA 
and  protein.  The  clinicopathologic  characteristics  of 
these  samples  including  the  genetic  evaluation  for 
VHL  mutational  status  are  shown  in  Table  3.  Both 
groups of ccRCCs were similar except for tumor size 
that was larger in sporadic tumors. Mutations were 
equally distributed throughout the sequence, and no 
particular gene phenotype association was found.  
As a proof of principle, several cell lines were 
tested  for  VHL  mRNA  expression.  The  results 
demonstrated that 786.O and UOK117 tumor cell lines 
having  VHL  mutations  had  indeed  low  transcript 
levels compared to the two normal kidney cell lines 
HRCE and HK-2 (Figure 3A). Likewise, VHL-/- ccRCC 
tumors had much lower transcript levels when com-
pared to sporadic tumors (Figure 3B), and a striking 
inverse correlation of miR-92a with VHL mRNA lev-
els was found (Figure 4A). A trend of higher miR-92a 
and miR-519d expression was seen in high Fuhrman 
nuclear grade tumors (Figure 4B-C).  
 
Figure  3.  VHL  transcript  evaluation  in  clear  cell  RCC 
(VHL-derived and sporadic) and cell lines. A. Two clear cell 
tumor-derived cell lines with different mutations showing 
decreased expression for VHL mRNA. B. Clear cell tumors 
arising in hereditary form had significantly lower transcript 
levels compared to sporadic cases.  Journal of Cancer 2011, 2 
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Figure 4. A. Influence of VHL-targeting microRNAs in VHL 
mRNA transcript levels. An inverse correlation between 
miR-92 expression and VHL mRNA levels was seen. B-C. 
Higher levels of miR-92a and miR-519d were seen in higher 
grade clear cell tumors. 
 
Hypoxia activation in clear cell RCC is fol-
lowed by miR-210 overexpression 
A  hallmark  of  ccRCCs  is  the  activation  of  hy-
poxia signaling mediated by HIF-1α accumulation. To 
test  the  hypothesis  that  the  hypoxia-regulated  mi-
croRNA-210  (miR-210)  is part  of  the  ccRCC  pheno-
type, we evaluated its expression in a series of clear 
cell  tumors  and  other  histologic  types  supposedly 
hypoxia-independent.  The  clinicopathologic  charac-
teristics of these samples are shown in Table 4. Clear 
cell tumors showed significantly higher miR-210 ex-
pression levels when compared to tumor of non-clear 
cell  histology  (9.90-fold  vs.  1.36,  p<0.001).  Tumors 
with sarcomatoid changes had the largest expression 
levels,  followed  by  both  sporadic  and  hereditary 
ccRCC.  Papillary  and  hybrid  oncocytic  tumors 
showed  significantly  lower  expression  levels  when 
compared to ccRCCs (Figure 5A). Interestingly, VHL 
mutations  in  exon  1,  deletions,  stop  mutations  and 
cases having more than 1 mutation in the gene had 
increased miR-210 expression (data not shown). Sim-
ilarly,  higher  Fuhrman  nuclear  grade  tumors  and 
tumors with lymph node metstasis showed increased 
expression levels of miR-210 (Figure 5B-C). 
 
 
Figure 5. Hypoxia-regulated miR-210 expression in RCCs 
and its correlation with some clinicopathologic parameters. 
A.  Clear  cell  tumors  including  some  with  sarcomatoid 
differentiation showed the highest expression levels com-
pared  to  RCC  tumors  of  non-clear  cell  histology.  B-C. 
Higher miR-120 expression was seen in high grade tumors 
and in lesions with positive lymph nodes.  Journal of Cancer 2011, 2 
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Table 3. Clinicopathologic characteristics of the patients with clear cell RCC (both VHL and sporadic). 
 
 
 
Discussion 
We have determined initially genome-wide ex-
pression changes of microRNAs in a group of kidney 
tumors  representing  a  spectrum  of  RCC  lesions. 
miRNA  profiling  of  these  tumors  demonstrated 
unique  expression  patterns  for  each  histologic  sub-
type. These results are in agreement and expand pre-
vious  attempts  on  the  subject.  Using  different  plat-
forms, two of the earliest publications (10, 29) identi-
fied  a  subset  of  miRNAs  that  were  mostly  un-
der-expressed  in  tumor  tissues,  including  miR-141 
and miR-200c, in a group of samples from  patients 
with clear cell and chromophobe RCCs. Several pub-
lications have followed (11, 30-34), many of them rep-
licating such initial findings despite variations in the 
technology used for expression analysis or statistical 
approaches.  
We decided to use a medium throughput, PCR 
array-based analysis which allowed increased sensi-
tivity for the detection of differentially expressed mi-
croRNAs for the initial profiling of our samples. We 
were able to detect microRNAs that are common de-
nominators for the most frequent type of kidney can-
cer, i.e. clear cell RCC. From these, miR-92a, miR-210 
and miR-200c appeared as significantly and differen-
tially  expressed  between  tumor  cells  and  normal 
kidney  parenchyma,  indicating  a  putative  role  in 
disease  pathogenesis.  Both  miR-210  and  miR-200c 
have  appeared  in  previous  attempts  to  profile  mi-
croRNA expression in clear cell RCC (10, 31, 32, 34, 
35). 
  Journal of Cancer 2011, 2 
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Table 4. Clinicopathologic features of patients and samples analyzed for miR-210 expression. 
 
 
 
Another major contribution of this work is that 
we  have  evaluated  a  genetically  defined  subset  of 
RCCs for microRNA expression which, as a difference 
with in previous work, has frequently resulted from 
pooling  of  samples  (30,  34).  While  the  microRNA 
signature can reflect differences in the underlying and 
unique molecular changes for each histologic type, its 
major clinical application could be on the classifica-
tion of normal and cancerous tissues as well as tumor 
categorization.  This  feature  can  prove  useful  for 
supporting the differential diagnosis or when defini-
tive classification is needed (36, 37). 
Consistent  with  bioinformatic  approaches,  ex-
perimental  data  supported  the  hypothesized  in-
volvement  of  miR-92a  in  clear  cell  tumors.  ccRCC 
expressed  increased  amount  of  miR92a  and  these 
tumors  showed  decreased  levels  of  VHL  mRNA, 
supporting the concept that microRNAs may influence 
transcript abundance of protein-coding target genes 
in RCC. miR-92a is a member of the 13q31 miRNA 
polycistron  (17-92  miRNA  cluster)  which  also  in-
cludes  miR-17,  miR-18a,  miR-19a,  miR-19b  and 
miR-20a (38, 39). Only few reports are available on the 
role of miR-92 specifically in cancer (40-42) or about 
its potential targeted genes. Ghosh et al. (41) described 
for  the  first  time  the  potential  role  of  miR-92  in 
chronic lymphocytic leukemia (CLL) linking miR-92 
and  hypoxia  signaling  through  HIF-1α  activation. 
miR-92 was found overexpressed in CLL B cells tar-
geting the VHL transcript, repressing its expression in 
this  model.  Almost  simultaneously  we  started  our 
initial work on the regulation of VHL by miR-92a (42). 
More recently, miR-92 has also been described to be 
involved in estrogen receptor beta (ERβ1) regulation 
in breast cancer (40). In that report, a negative corre-
lation between ERβ1 expression and miR-92 in a series 
of breast cancer tissues and cell lines was found, fur-
ther  implicating  a  role  for  miR-92  in  breast  cancer 
pathogenesis.  
 Our data is also consistent with the results from 
independent  groups  analyzing  clear  cell  RCCs  that 
demonstrate increased expression of other members 
of the miR17-92 cluster at significantly higher levels 
than normal kidney (35). In a series of fifteen paired 
tumor and normal tissues from patients with clear cell 
RCC, Chow et al. (35) demonstrated not only that tu-
mors overexpressed miR-17-5p, 18a and 20a but also 
that they have specific roles in the regulation of cell 
proliferation in vitro. Also in line with our results of an 
overexpression of miR-92a in clear cell kidney cancer, 
miR-17-5p  and  its  cluster  miR-17-92  have  been  ob-
served overexpressed in human lung, breast, colon, 
pancreas, and prostate cancers (14, 38). Furthermore, 
overexpression  of miR-17-5p has been associated to  Journal of Cancer 2011, 2 
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c-Myc amplification, accelerating tumor development 
in a mouse B-cell lymphoma model, and thus indi-
cating an oncogenic role for this microRNA (39).  
Lastly, we found evidence that the activation of 
some hypoxia-responsive microRNAs are part of the 
cascade  of  events  following  VHL  gene  inactivation, 
and that the expression of such microRNAs may be 
related  to  a  more  aggressive  phenotype.  Clear  cell 
tumors,  either  in  sporadic  or  hereditary  forms, 
showed significantly higher levels of miR-210 when 
compared to other histologic types, and higher levels 
were  seen  in  higher  grade  tumors  of  lesions  with 
lymph node metastasis. Kulshreshtha et al. (25) doc-
umented for the first time the expression pattern of 
microRNAs in cell lines as induced by hypoxia. The 
study  uncovered  many  hypoxia-regulated  miRNAs, 
several  of  them  –miR210,  miR21-  also  described  as 
upregulated in clear cell RCC. In kidney cancer, four 
out of 8 studies (31, 32, 35, 43), including our own, 
show  miR210  in  the  top  list  of  upregulated  mi-
croRNAs in clear cell RCC.  
This finding is not unique to RCC. Camps et al. 
(28) identified and validated that in low oxygen lev-
els, miR-210 had the most significant change in breast 
cancer. They also showed evidence that this response 
is mediated through the Hypoxia Inducible Factor-1 
alpha  (HIF-1α)/Von  Hippel  Lindau  (VHL)  tumor 
suppressor system. Several other studies now point to 
miR-210  as  the  most  ubiquitously  upregulated  mi-
croRNA by HIF-1α in different tumor types and cell 
lines (44).  
In summary, our data show consistent disregu-
lation of miRNAs in human kidney cancer, some of 
which are potentially involved in critical gene silenc-
ing in RCC and others that are activated as part of the 
pathophysiological response in these tumors, impli-
cating a major role for microRNA expression in every 
step of RCC pathogenesis. The results of this study 
uncover  an  etiological  contribution  of  miRNAs  in 
RCC and validate their use for future studies on the 
role of individual miRNAs in disease progression that 
could  be  used  for  development  of  miRNA-based 
therapeutic strategies. A more detailed understanding 
of  the  molecular  mechanisms  and  regulatory  path-
ways at work in RCC will enormously assist in im-
proving the design and target selection of therapeutic 
strategies.  
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